						<u> </u>	Sheet _1	<u> of _</u>	
J.S. Depart	tment	of Commerce,	Patent and T	rademark Office	Atty Do	cket No.	Serial	No.	
						PC-0022 CIP		09/747,524	
LIST OF REFERENCES CITED BY APPLICANTS IPE					Applicant(s)				
	(Use	e several shee	ts if necess	-/	Tang et	al.			
MAR 0 8 2001					Filing Date		Group		
			· · · · · · · · · · · · · · · · · · ·		Decembe	r 19, 2000	To Be A	ssigne	
			U.S.	Patenta DeMaments					
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
			Forcia	n Patent Deguments	<u> </u>				
			roreig	n Patent Documents	5		Tranc	lation	
		Document	Date	Country	Class	Subclass	Yes	No	
	OTI	HER ART (In	cluding Auth	nor, Title, Date,	Pertiner	nt Pages, E	tc.)	•	
M	1	Muller and Bendtzen, "1,25-Dihydroxyvitamin $D_3$ as a Natural Regulator of Human Immune Functions", J. Investig. Dermatol. Symp. Proc. 1:68-71 (1996)							
1	2	Lemire, J., 1,25-Dihydroxyvitamin D3a hormone with immunomodulatory properties', Z. Rheumatol. 59 Suppl.1:24-27 (2000)							
	3	Wiers et al., "1α,25-Dihydroxyvitamin D3 activates T Cells of Tumor bearer through protein phosphatase 2A", Cancer Immunol. Immunother. 44:97-102 (199							
	4	Wellmann et al., "Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas", Blood 96:398-404 (2000)							
	5	Rattus norvegicus HW051 (Geneseq W86321) (Abstract Only)							
V	6	Bolton, A.E. and Hunter, W. M., "The Labelling of Proteins to High Specific Radioactivites by Conjugation to a <sup>125</sup> I-Containing Acylating Agent", Bioche J. 133:529-539 (1973)							
				-					
								<u>-</u>	
		-							
					<u> </u>			<del></del>	
	_	., .,,	<del></del> .		<u> </u>				
-	<del></del>		·						
		<del>  ()                                   </del>				<del>,</del>			
Examiner	m		Date Consid	dered 5/29/1/2					
EXAMINER:	Init	tial if refere	nce consider	red, whether or no	t citati	on is in c	onformanc	e with	
coo					_			_	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.